What is Science?
Science Corporation is recognized in the industry as a clinical-stage medical technology firm dedicated to pioneering neural interface and neuro-engineering solutions. The company's core mission revolves around enhancing human health by developing advanced biohybrid neural interfaces and devices. These innovations are designed to restore critical functions such as vision, cognition, and mobility for individuals affected by serious neurological conditions. Science leverages a vertically integrated infrastructure, combining cutting-edge research and clinical work to accelerate the transition of its discoveries from the laboratory to patient applications.
How much funding has Science raised?
Science has raised a total of $230M across 1 funding round:
Series C
$230M
Series C (2026): $230M with participation from In-Q-Tel, Quiet Capital, Lightspeed Venture Partners, Khosla Ventures, and Y Combinator
Key Investors in Science
In-Q-Tel
In-Q-Tel (IQT) is a not-for-profit strategic investment firm that serves as the U.S. national security community's venture arm, focusing on early-stage commercial technology companies in sectors like biotech and AI.
Quiet Capital
Quiet Capital is a founder-led venture capital firm that supports ambitious technology entrepreneurs across software, financial, health, and industrial markets with patient capital and operational expertise.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage venture capital firm investing in early and growth-stage technology companies across enterprise software, consumer, and fintech, from seed to IPO.
What's next for Science?
With the recent influx of major strategic investment and substantial total funding, Science is poised for accelerated growth and development. This significant capital infusion is expected to fuel the expansion of its research and development initiatives, clinical trials, and the scaling of its manufacturing capabilities. The company's focus on addressing unmet needs in neurological conditions positions it for substantial impact. Future endeavors will likely concentrate on navigating regulatory pathways and broadening the accessibility of its neuro-engineering solutions to a wider patient population, solidifying its role as a leader in the medical technology sector.
See full Science company page
